Collegium Pharmaceutical (COLL) Operating Expenses (2014 - 2026)

Collegium Pharmaceutical has reported Operating Expenses for 13 years, with the latest figure at $106.6 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 45.46% year-over-year to $106.6 million in Q2 2026; TTM through Jun 2026 was $327.6 million, a 20.88% increase from a year earlier, with the FY2025 full-year figure at $283.6 million, up 36.72% from the prior year.
• Operating Expenses was $106.6 million for Q2 2026 at Collegium Pharmaceutical, up from $86.4 million in the prior quarter.
• The five-year high for Operating Expenses was $106.6 million in Q2 2026, with the low at $32.9 million in Q4 2023.
• Average Operating Expenses over 5 years is $56.6 million, with a median of $55.6 million recorded in 2022.
• The largest YoY upside for Operating Expenses was 82.68% in 2024 against a maximum downside of 20.45% in 2024.
• Over 5 years, Operating Expenses stood at $38.0 million in 2022, then declined by 13.38% to $32.9 million in 2023, then soared by 82.68% to $60.2 million in 2024, then climbed by 12.37% to $67.6 million in 2025, then surged by 57.63% to $106.6 million in 2026.
• The last three Operating Expenses figures came in at $106.6 million (Q2 2026), $86.4 million (Q1 2026), and $67.6 million (Q4 2025), per Business Quant data.